Literature DB >> 3011676

Low endotoxic activities of synthetic Salmonella-type lipid A with an additional acyloxyacyl group on the 2-amino group of beta (1-6) glucosamine disaccharide 1,4'-bisphosphate.

S Kotani, H Takada, I Takahashi, M Tsujimoto, T Ogawa, T Ikeda, K Harada, H Okamura, T Tamura, S Tanaka.   

Abstract

A synthetic lipid A (Salmonella type, compound 516), beta (1-6)-linked D-glucosamine disaccharide 1,4'-bisphosphate, with three acyloxyacyl groups and one hydroxyacyl group, i.e., (R)-3-hexadecanoyloxytetradecanoyl, (R)-3-hydroxytetradecanoyl, (R)-3-dodecanoyloxytetradecanoyl, and (R)-3-tetradecanoyloxytetradecanoyl groups at the 2-amino, 3-hydroxyl, 2'-amino, and 3'-hydroxyl groups, respectively, was less biologically active than the synthetic Escherichia coli-type lipid A (compound 506), which has only two acyloxyacyl groups at the 2' and 3' positions and is substituted with a (R)-3-hydroxytetradecanoyl group at the 2-amino group. Compound 516 exhibited considerably weaker pyrogenic and leukopenic activity than compound 506, and it scarcely prepared rabbit skin for the Shwartzman reaction and lacked lethal toxicity on chicken embryos, although its lethal toxicity in galactosamine-loaded mice was as strong as that of compound 506. Compound 516 was also less active than compound 506 or natural E. coli lipid A (from Restrain F515) in other biological test systems, such as the Limulus test, stimulation of macrophages and lymphocytes, and interferon-inducing activity but not for interleukin-1 induction or complement activation. This observation suggests that there is an optimal number of acyloxyacyl groups on the glucosamine backbone for producing the biological activities of lipid A, especially the endotoxic activities. The 4'-monophosphate analog (compound 514) of compound 516 in general had significantly weaker activity than compound 516 in the above assays, most probably because of its greater hydrophobicity and consequently lower solubility in assay systems. Bacterial R595 lipid A derived from S. minnesota Re-mutant, which is a mixture of compounds 516 and 506, their 4'-monophosphate analogs and other compounds, exerted intermediate degrees of activity between compounds 506 and 516 in the various test systems employed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011676      PMCID: PMC260942          DOI: 10.1128/iai.52.3.872-884.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  OBSERVATIONS ON MODE OF ACTION OF ENDOTOXIN IN CHICK EMBRYOS.

Authors:  R A FINKELSTEIN
Journal:  Proc Soc Exp Biol Med       Date:  1964-03

2.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

Review 3.  Chemistry and immunochemistry of bacterial lipopolysaccharides as cell wall antigens and endotoxins.

Authors:  O Westphal; K Jann; K Himmelspach
Journal:  Prog Allergy       Date:  1983

4.  Immunobiologically active lipid A analogs synthesized according to a revised structural model of natural lipid A.

Authors:  S Kotani; H Takada; M Tsujimoto; T Ogawa; K Harada; Y Mori; A Kawasaki; A Tanaka; S Nagao; S Tanaka
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

5.  Endotoxic glycolipid as a potent depressor of the hepatic drug-metabolizing enzyme systems in mice.

Authors:  K Egawa; N Kasai
Journal:  Microbiol Immunol       Date:  1979       Impact factor: 1.955

6.  Galactosamine-induced sensitization to the lethal effects of endotoxin.

Authors:  C Galanos; M A Freudenberg; W Reutter
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

7.  Production of an anti-tumour cytotoxin by human monocytes.

Authors:  N Matthews
Journal:  Immunology       Date:  1981-09       Impact factor: 7.397

8.  Induction of interleukin 1 secretion by adjuvant-active peptidoglycans.

Authors:  F Vacheron; M Guenounou; C Nauciel
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

9.  Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium.

Authors:  N Qureshi; K Takayama; E Ribi
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

10.  High-level induction of gamma interferon with various mitogens in mice pretreated with Propionibacterium acnes.

Authors:  H Okamura; K Kawaguchi; K Shoji; Y Kawade
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

View more
  13 in total

1.  Biological properties of lipid A isolated from Flavobacterium meningosepticum.

Authors:  K Tanamoto; H Kato; Y Haishima; S Azumi
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Somnogenic activities of synthetic lipid A.

Authors:  A B Cady; S Kotani; T Shiba; S Kusumoto; J M Krueger
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

3.  Crystallization of R-form lipopolysaccharides from Salmonella minnesota and Escherichia coli.

Authors:  N Kato; M Ohta; N Kido; H Ito; S Naito; T Hasegawa; T Watabe; K Sasaki
Journal:  J Bacteriol       Date:  1990-03       Impact factor: 3.490

4.  Ultrafiltration to reject human interleukin-1-inducing substances derived from bacterial cultures.

Authors:  C A Dinarello; G Lonnemann; R Maxwell; S Shaldon
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

5.  The polysaccharide portion plays an indispensable role in Salmonella lipopolysaccharide-induced activation of NF-kappaB through human toll-like receptor 4.

Authors:  Masashi Muroi; Ken-Ichi Tanamoto
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

6.  Chemical and biological characterization of the lipopolysaccharide of the oral pathogen Wolinella recta ATCC 33238.

Authors:  J Gillespie; S T Weintraub; G G Wong; S C Holt
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

7.  Immunobiological activities of synthetic lipid A analogs with low endotoxicity.

Authors:  S Kotani; H Takada; I Takahashi; T Ogawa; M Tsujimoto; H Shimauchi; T Ikeda; H Okamura; T Tamura; K Harada
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

8.  Endotoxic induction of prostaglandin release from macrophages by nontoxic lipid A analogs synthesized chemically.

Authors:  K Tanamoto; U Shade; E T Rietschel; S Kusumuto; T Shiba
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

Review 9.  Molecular adjuvants and immunomodulators: new approaches to immunization.

Authors:  A G Johnson
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

10.  Lipid A in Helicobacter pylori.

Authors:  I Mattsby-Baltzer; Z Mielniczuk; L Larsson; K Lindgren; S Goodwin
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.